



September 28, 2015

Re: Influenza Vaccine

Dear IEHP Provider:

On August 7, 2015, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) published the updated recommendations regarding the use of influenza vaccine for the 2015-2016 influenza season. The primary changes and updated recommendations are as follows:

(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm#Groups_Recommended_Vaccination_Timing_Vaccination)

For 2015–16, ACIP recommends the following:

1. All persons aged ≥ 6 months should receive influenza vaccine annually. Influenza vaccination should not be delayed to procure a specific vaccine preparation if an appropriate one is already available.
2. For healthy children aged 2 through 8 years who have no contraindications or precautions, either LAIV or IIV is an appropriate option. No preference is expressed for LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is appropriate. An age-appropriate formulation of vaccine should be used.
3. LAIV should not be used in the following populations:
 - o Persons aged < 2 years or > 49 years;
 - o Persons with contraindications listed in the package insert:
 - Children aged 2 through 17 years who are receiving aspirin or aspirin-containing products;
 - Persons who have experienced severe allergic reactions to the vaccine or any of its components, or to a previous dose of any influenza vaccine;
 - o Pregnant women;
 - o Immunocompromised persons (see also "Vaccine Selection and Timing of Vaccination for Immunocompromised Persons");
 - o Persons with a history of egg allergy;
 - o Children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma within the last 12 months. For persons aged ≥ 5 years with asthma, recommendations are described in item 4 of this list;

- Persons who have taken influenza antiviral medications within the previous 48 hours.
4. In addition to the groups for whom LAIV is not recommended above, the "Warnings and Precautions" section of the LAIV package insert indicates that persons of any age with asthma might be at increased risk for wheezing after administration of LAIV. The package insert also notes that the safety of LAIV in persons with other underlying medical conditions that might predispose them to complications after wild-type influenza virus infection (e.g., chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus]), has not been established. These conditions, in addition to asthma in persons aged ≥ 5 years, should be considered precautions for the use of LAIV.
 5. Persons who care for severely immunosuppressed persons who require a protective environment should not receive LAIV, or should avoid contact with such persons for 7 days after receipt, given the theoretical risk for transmission of the live attenuated vaccine virus to close contacts.

Coverage

VFC covered vaccines

VFC (Vaccines for Children)-eligible children who are aged 6 months through 18 years should receive influenza vaccination through VFC program.

IEHP Medi-Cal (Over 18 years old), Healthy Kids and Medicare DualChoice (HMO SNP) and Medicare DualChoice Cal MediConnect Plan (Medicare- Medicaid Plan)

IEHP will reimburse practitioners the cost of the vaccine for IEHP Medi-Cal (over 18 years old), Healthy Kids, Medicare DualChoice (HMO SNP) and Medicare DualChoice Cal MediConnect Plan (Medicare- Medicaid Plan) Members by line of business (Medi-Cal / Medicare Rate). Submit your completed CMS1500 claim form with the correct CPT code to **IEHP Claims Dept.**, P.O. Box 4349, Rancho Cucamonga, CA 91729-4349.

IEHP Medi-Cal (Over 18 years old), Healthy Kids

CPT CODE	DRUG NAME & DOSE	VACCINE
90654	Fluzone Intradermal	Influenza virus vaccine, split virus, 18 years and above dosage, for intradermal (single dose)
90655	Fluzone 0.25mL	Influenza virus vaccine, split virus, preservative free , 6-35 months dosage, for intramuscular (single dose)
90656	Afluria 0.5mL Fluzone 0.5mL	Influenza virus vaccine, split virus, preservative free , 3 years and above dosage, for intramuscular (single dose)

	Fluarix 0.5mL Fluvirin 0.5mL	
90657	Fluzone 0.25mL	Influenza virus vaccine, split virus, 6-35 months dosage, for intramuscular
90658	Afluria 0.5mL Fluzone 0.5mL Fluvirin 0.5mL	Influenza virus vaccine, split virus, 3 years and above dosage, for intramuscular
90662	Fluzone High Dose	Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular
90685	Fluzone Quad (0.25mL) Fluarix Quad (0.25mL)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
90686	Fluzone Quad (0.5mL) Fluarix Quad (0.5mL)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use
90687	Fluzone Quad (0.25mL) Fluarix Quad (0.25mL)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
90688	Fluzone Quad (0.5mL) Fluarix Quad (0.5mL)	Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use

IEHP Medicare DualChoice (HMO SNP) and Medicare DualChoice Cal MediConnect Plan (Medicare- Medicaid Plan) - (Part B covered Vaccine)

10801 6th St., Suite 120, Rancho Cucamonga, CA 91730
 Tel (909) 890-2067 Fax (909) 891-1577
 Visit our web site at: www.iehp.org

CPT CODE	DRUG NAME & DOSE	VACCINE
90630	Fluzone Intradermal Quad	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
90654	Fluzone Intradermal	Influenza virus vaccine, split virus, 18 years and above dosage, for intradermal (single dose)
90655	Fluzone 0.25mL	Influenza virus vaccine, split virus, preservative free , 6-35 months dosage, for intramuscular (single dose)
90656	Afluria 0.5mL Fluzone 0.5mL Fluarix 0.5mL Fluvirin 0.5mL	Influenza virus vaccine, split virus, preservative free , 3 years and above dosage, for intramuscular (single dose)
90657	Fluzone 0.25mL	Influenza virus vaccine, split virus, 6-35 months dosage, for intramuscular
90661	Flucelvax	Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use, 18 years and above dosage, for intramuscular
90662	Fluzone High Dose	Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular
90672	Flumist Quadrivalent	Influenza virus vaccine, quadrivalent (LAIV), live, intranasal use
90673	Flublok	Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, 18 years and above dosage, for intramuscular use
90685	Fluzone Quad (0.25mL) Fluarix Quad (0.25mL)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
90686	Fluzone Quad (0.5mL) Fluarix Quad (0.5mL)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use


90687	Fluzone Quad (0.25mL) Fluarix Quad (0.25mL)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6-35 months of age, for intramuscular use
90688	Fluzone Quad (0.5mL) Fluarix Quad (0.5mL)	Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use

MEDICARE CODE	DRUG NAME	VACCINE
Q2035	Afluria	Influenza virus vaccine, split virus, 3 years and above dosage, for intramuscular
Q2036	Flulaval	Influenza virus vaccine, split virus, 3 years and above dosage, for intramuscular
Q2037	Fluvirin	Influenza virus vaccine, split virus, 3 years and above dosage, for intramuscular
Q2038	Fluzone	Influenza virus vaccine, split virus, 3 years and above dosage, for intramuscular

Information regarding influenza surveillance, prevention, detection, and control is available on CDC/NCID's website at <http://www.cdc.gov/flu/>. Surveillance information is available through the CDC Voice Information System at 888-CDC-FACT (888-232-3228) or CDC Fax Information Service at 888-CDC-FAXX (888-232-3299).

Should you have any questions regarding the above, please call us at (909) 890-2067.

Sincerely,



William Henning, D.O.
 Chief Medical Officer